Roche’s Gazyva fell short in a late-stage lymphoma trial, jeopardizing the company’s expansion plans for the Rituxan follow-up. As a new-and-improved version of Roche’s best-selling drug, Gazyva is the Swiss drugmaker’s answer to impending biosimilars. If Gazyva wants to fill the sales gap after biosims hit, it will need to expand into new groups of patients–and this lymphoma type was meant to be one of them.

Source: Lymphoma trial failure endangers Roche’s Gazyva growth plans as Rituxan biosims loom | FiercePharma